Publication date: Mar 06, 2020
Xconomy San Diego – A 20-patient Phase 1 study of an RNA drug discovered by Ionis Pharmaceuticals that is being tested as a treatment for Huntington’s disease by Roche was suspended after two reports of infections related to a device used to take samples of cerebral spinal fluid during the trial.
The suspension doesn’t appear to be related to the drug, tominersen, and no other trials of the investigational treatment were impacted-including an ongoing global Phase 3 study due to read out in 2022.
Historically Ionis has partnered many of its programs, such as the potential Huntington’s disease drug.
All of its clinical-stage neurological programs, for example, in addition to the Huntington’s program, are partnered: potential treatments for amyotrophic lateral sclerosis, Alzheimer’s disease, and frontotemporal degeneration are being advanced by Biogen (NASDAQ: BIIB), and an investigational centronuclear myopathy drug is under evalution by Dynacure.
Of the 40 drugs Ionis has under development, it controls include investigational treatments for a handful of rare diseases, including agromegaly, hereditary angioedema, beta thalassemia, and cystic fibrosis; and an experimental drug for treatment-resistant hypertension.
|disease||MESH||amyotrophic lateral sclerosis|
- Chugai’s Huntington’s disease drug, RG6042 gets Japanese orphan drug designation
- Step Aside, CRISPR: RNA Editing is Taking Off